Mamta Parikh

Title(s)Associate Professor, MED: Int Med Hematology/Oncology
SchoolSchool of Medicine
AddressCancer Ctr, 4501 X Street, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    I am a clinical researcher focusing on genitourinary malignancies, with a growing interest in cancer research education.

    Collapse Biography 
    Collapse education and training
    Boston University, Boston, MABSChemistry
    University of California, Irvine, Irvine, CAMSChemistry
    University of California, Davis, Sacramento, CAMD
    University of California, Davis, Sacramento, CA06/2014Internal Medicine Residency
    University of California, Davis, Sacramento, CA06/2017Hematology Oncology Fellowship

    Collapse Research 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer. Nanomedicine (Lond). 2026 Jun 01; 1-6. Narayan A, Leibrandt RC, Lee JS, Dall'Era MA, Whitson JM, Chandrasekar T, Braun A, Mossanen M, Li H, Lara PN, Lam KS, Pan CX, Parikh M. PMID: 42226594.
      View in: PubMed   Mentions:    Fields:    
    2. Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). J Clin Oncol. 2026 May 07; JCO2502835. McKay RR, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Manning DK, Olson A, Parikh M, Parikh R, Saraiya B, Pasquina LW, Madison R, Clifford S, Childress M, Gasco A, Ivy P, Van Allen E, Kochupurakkal B, Shapiro GI. PMID: 42096662.
      View in: PubMed   Mentions:    Fields:    
    3. IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2026 May 04; 25(5):786-798. Leslie AR, Ning S, Sharifi M, Schaaf ZA, Maine JP, Lou W, Leslie KD, Liu C, Xu H, Lombard AP, Chen HW, Parikh M, Dall'Era M, Gao AC. PMID: 41347288; PMCID: PMC12795166.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    4. Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer. J Natl Compr Canc Netw. 2026 May; 24(5). Brown JR, Parikh M. PMID: 42134402.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer. Biomedicines. 2026 Apr 22; 14(5). Correa Gonzalez B, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, McPherson JD, Li H, Parikh M, Dall'Era M, Gao AC, Lombard AP. PMID: 42193276; PMCID: PMC13203762.
      View in: PubMed   Mentions:
    6. Retrospective, Observational Analysis of Real-World Safety Outcomes in Patients With Locally Advanced/Metastatic Urothelial Cancer Treated With Sacituzumab Govitecan. Clin Genitourin Cancer. 2026 Apr; 24(3):102516. Parikh M, McMahon P, Eng S, Boateng F, Ghazi Y, Schmidt K, Brockman M, Ma X, Sierecki M. PMID: 41807147.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Association of Guideline-Concordant Care with Survival in Adolescent and Young Adult Patients with Germ Cell Tumors. J Adolesc Young Adult Oncol. 2026 02; 15(1):29-39. Alvarez E, Malogolowkin M, Frazier AL, Li Q, Brunson A, Maguire F, Abrahao R, Parikh M, Chen H, Keegan THM. PMID: 40498596.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404). Cancer Res Commun. 2025 Nov 01; 5(11):1946-1951. Parikh M, Uboha NV, Takebe N, Tam K, Bedard PL, Wisinski KB, Mittra A, Yin M, Yang Y, Noonan AM, Holleran JL, Ruel C, Frankel P, Beumer JH, Newman EM, Danilov AV, Gore SD, Lara PN. PMID: 41104717; PMCID: PMC12580894.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    9. Academic research careers for medical doctors (ARC-MD): a five-year UC Davis training program to foster the next generation of physician-scientists. Med Educ Online. 2025 Dec 31; 30(1):2568575. Parikh M, Rosenthal JL, Santana LF, Meyers FJ. PMID: 41077733; PMCID: PMC12519581.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer. Endocr Relat Cancer. 2025 Jun 01; 32(6). Liang A, Gulati S, Huang Q, Dowst H, Lim A, Zarrin-Khameh N, Godoy G, Noor AB, Castro P, Scheurer ME, Parikh M, Lara PN, Hilsenbeck S, Mims M, Mitsiades N. PMID: 40310703; PMCID: PMC12230269.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Divergences in neuroendocrine prostate cancer frequency as recognized by anatomic pathologists, clinicians, and basic scientists. Asian J Androl. 2025 Jan 01; 27(1):1-3. Iczkowski KA, Parikh M. PMID: 39162145; PMCID: PMC11784960.
      View in: PubMed   Mentions:    Fields:    
    12. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801. Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. PMID: 38920407; PMCID: PMC11264598.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    13. High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET. J Nucl Med. 2024 05 01; 65(5):714-721. Wang Y, Abdelhafez YG, Spencer BA, Verma R, Parikh M, Stollenwerk N, Nardo L, Jones T, Badawi RD, Cherry SR, Wang G. PMID: 38548347; PMCID: PMC11064825.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 05; 22(4):216-225. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. PMID: 38754471.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    15. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104. Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N. PMID: 38523017; PMCID: PMC12037053.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    16. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer Prostatic Dis. 2024 Sep; 27(3):566-570. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. PMID: 38424319; PMCID: PMC12036820.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    17. Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2024 04; 22(2):217-223. Mar N, Dwabe S, Baranda MN, Zarrabi KK, Eturi A, Gulati S, Parikh M, Seyedin SN, Kalebasty AR. PMID: 38087703.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Prostate cancer and bone: clinical presentation and molecular mechanisms. Endocr Relat Cancer. 2023 09 01; 30(9). Wells KV, Krackeler ML, Jathal MK, Parikh M, Ghosh PM, Leach JK, Genetos DC. PMID: 37226936; PMCID: PMC10696925.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer. Sci Rep. 2023 06 14; 13(1):9617. Steele TM, Tsamouri MM, Siddiqui S, Lucchesi CA, Vasilatis D, Mooso BA, Durbin-Johnson BP, Ma AH, Hejazi N, Parikh M, Mudryj M, Pan CX, Ghosh PM. PMID: 37316561; PMCID: PMC10267166.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    20. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. Eur Urol. 2024 Feb; 85(2):171-176. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, Agarwal N. PMID: 37085425; PMCID: PMC10662935.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    21. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). Mol Cancer Ther. 2023 04 03; 22(4):511-518. Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Ivy SP, Van Allen EM, Lindeman NI, Kochupurakkal BS, Shapiro GI, McKay RR. PMID: 36780008; PMCID: PMC10769512.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    22. ATR Inhibition in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2023 04; 21(2):203-207. Leibrandt RC, Tu MJ, Yu AM, Lara PN, Parikh M. PMID: 36604210; PMCID: PMC10750798.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    23. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol. 2023 01 20; 41(3):640-650. Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, Devitt M, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, Dreicer R, Gill PS. PMID: 35984996.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    24. Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. Kidney Cancer. 2022; 6(2):105-107. Parikh M, Lara PN. PMID: 36212798; PMCID: PMC9490427.
      View in: PubMed   Mentions: 1  
    25. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. PMID: 35948037.
      View in: PubMed   Mentions: 148     Fields:    Translation:Humans
    26. Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report. J Gastrointest Oncol. 2022 Jun; 13(3):1473-1480. Hsieh-Wong J, Liu J, Huynh J, Parikh M, Kim E, Gong J, Halabi W, Siricilla M, Mitra A, Toomey K, Cho M. PMID: 35837187; PMCID: PMC9274065.
      View in: PubMed   Mentions: 1  
    27. Development of a survey to assess the impact of substance use disorder education on student pharmacists' perspective. Curr Pharm Teach Learn. 2022 04; 14(4):462-467. Chebabo-Weiner S, Williams SN, Parikh M, Wharton S, Patel T. PMID: 35483812.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Untargeted Metabolomics Identify a Panel of Urinary Biomarkers for the Diagnosis of Urothelial Carcinoma of the Bladder, as Compared to Urolithiasis with or without Urinary Tract Infection in Dogs. Metabolites. 2022 Feb 24; 12(3). Tsamouri MM, Durbin-Johnson BP, Culp WTN, Palm CA, Parikh M, Kent MS, Ghosh PM. PMID: 35323643; PMCID: PMC8951005.
      View in: PubMed   Mentions: 9  
    29. Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling. J Nucl Med. 2022 08; 63(8):1274-1281. Wang G, Nardo L, Parikh M, Abdelhafez YG, Li E, Spencer BA, Qi J, Jones T, Cherry SR, Badawi RD. PMID: 34795014; PMCID: PMC9364337.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    30. Routine Bone Imaging for Metastatic Renal Cell Carcinoma: Is it Time? J Kidney Cancer VHL. 2021; 8(4):20-21. Parikh M. PMID: 34722127; PMCID: PMC8523176.
      View in: PubMed   Mentions:
    31. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 01; 7(10):1536-1543. Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, Lyou Y, Weng P, Parikh R, Teply B, Dreicer R, Emamekhoo H, Michaelson D, Hoimes C, Zhang T, Srinivas S, Kim WY, Cui Y, Newman E, Lara PN. PMID: 34436521; PMCID: PMC8391778.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    32. Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. Am Soc Clin Oncol Educ Book. 2021 Jun; 41:e182-e189. Parikh M, Powles T. PMID: 34061558.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    33. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Sci Rep. 2021 03 18; 11(1):6377. Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. PMID: 33737681; PMCID: PMC7973745.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    34. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. Semin Nephrol. 2020 01; 40(1):76-85. Parikh M, Bajwa P. PMID: 32130969; PMCID: PMC7164329.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    35. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. Clin Genitourin Cancer. 2018 12; 16(6):421-428.e1. Parikh M, Pan CX, Beckett LA, Li Y, Robles DA, Aujla PK, Lara PN. PMID: 30166228; PMCID: PMC6450697.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    36. Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer. Cancer Treat Res Commun. 2018; 16:38-44. Parikh M, Galkin M, Brunson A, Keegan T, Chew HK. PMID: 31299001.
      View in: PubMed   Mentions: 3     Fields:    
    37. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type. Annu Rev Med. 2018 01 29; 69:209-221. Parikh M, Lara PN. PMID: 29144835.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    38. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol. 2017; 2017. Lara PN, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. PMID: 29629426; PMCID: PMC5884164.
      View in: PubMed   Mentions: 9     Fields:    
    39. New and emerging developments in extensive-stage small cell lung cancer therapeutics. Curr Opin Oncol. 2016 Mar; 28(2):97-103. Parikh M, Riess J, Lara PN. PMID: 26844984; PMCID: PMC5139911.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    40. Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists. Bioorg Med Chem Lett. 2004 Nov 15; 14(22):5599-603. DeVita RJ, Parikh M, Jiang J, Fair JA, Young JR, Walsh TF, Goulet MT, Lo JL, Ren N, Yudkovitz JB, Cui J, Yang YT, Cheng K, Rohrer SP, Wyvratt MJ. PMID: 15482932.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    41. Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists. Bioorg Med Chem Lett. 2001 Apr 23; 11(8):1077-80. Lin P, Parikh M, Lo JL, Yang YT, Cheng K, Smith RG, Fisher MH, Wyvratt MJ, Goulet MT. PMID: 11327594.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    42. A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor. J Med Chem. 2001 Mar 15; 44(6):917-22. DeVita RJ, Walsh TF, Young JR, Jiang J, Ujjainwalla F, Toupence RB, Parikh M, Huang SX, Fair JA, Goulet MT, Wyvratt MJ, Lo JL, Ren N, Yudkovitz JB, Yang YT, Cheng K, Cui J, Mount G, Rohrer SP, Schaeffer JM, Rhodes L, Drisko JE, McGowan E, MacIntyre DE, Vincent S, Carlin JR, Cameron J, Smith RG. PMID: 11300873.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    43. Inverse electron demand diels-alder reactions of indole IV. A new route to ß-carbolines. Tetrahedron Letters. 1995 Sep 1; 36(37):6591-6594. Fan FW, Parikh PM, Snyder SJ. .
      View in: Publisher Site   Mentions:
    Mamta's Networks
    Concepts (167)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (60)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-34-g86efa0e9 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California